5th Annual West Oncology Conference at Graceland: Advances in the Business of Science of Oncology
J

Treatment Options in R/R Multiple Myeloma: Tips for Selecting Among the Myriad Of Choices

By 5th Annual West Oncology Conference at Graceland: Advances in the Business of Science of Oncology FEATURING Jesus Berdeja
March 2020
0 Comments
Login to view comments. Click here to Login

Related Content

AUTOPLAY
Indy Hematology Review

17th Indy Hematology Review

Sat, Aug 15, 2020
25:51
KU ASH 2018 Review: Current Updates in Hematologic Diseases

MM - Overview of Trials Presented at ASH 2018

Feat. A. Abdallah
08:15
2018 Pan Pacific Lymphoma Conference

Evolution of Myeloma Induction Regimens

Feat. S. Holstein
12:03
Andrew Cowan

BCMA CAR-T + Gamma Secretase Inhibitor Appear to Be Well Tolerated in R/...

12:16
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Discrepancy Between Real World vs. Clinical Trial Data in Relapsed/Refra...

Feat. M. Dimopoulos
15:31
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

ASH 2019 Relapsed Myeloma Highlights: Can Biomarkers Predict Response to...

Feat. A. Rosko
09:50
Nina Shah

Maximizing the Initial Gains in Myeloma Therapy: Consolidation and Maint...

19:41
Peter Voorhees

Approach to the Patient with Refractory & Multiple Relapsed Multiple Mye...

10:30
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)

Next Questions in Myeloma: Biology, Smoldering Myeloma, High-risk, MRD, ...

Feat. S. Jagannath
06:12
Indy Hematology Review

Targeting Mutations in Myeloma with Venetoclax and Development of the Fi...

Feat. K. Anderson
15:02
Krina Patel

Clinical Trials in Myeloma in 2018

15:11
Ajay Nooka

Early Relapse: Choosing Among Different Second Line Regimens in Myeloma

14:15
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

MRD in Multiple Myeloma Isn't Ready for Prime Time: More Patients Can Ac...

Feat. T. Martin
16:22
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)

FDA Approves Selinexor for Refractory Multiple Myeloma, STORM Study

Feat. S. Jagannath
12:32
Indy Hematology Review

What's New in Immunotherapy and Genomics in Multiple Myeloma?

Feat. K. Anderson
15:47
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)

Myeloma State of the Art Update: Bone Disease, MRD Assessment, How to Ma...

Feat. S. Lonial
09:02
Maria-Victoria Mateos

FDA Approves Once-Weekly Carfilzomib Regimen for Myeloma

15:10
Krina Patel

Developing CAR T-cells in Multiple Myeloma

15:31
Parameswaran Hari

Refractory and Relapsing Myeloma - When to Treat and Options Available

14:43
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)

What Will The Future Hold for Myeloma Treatment CARTs vs BiTES?

Feat. R. Orlowski
17:58
City of Hope

Should Everyone Receive Monoclonal Antibodies at First Myeloma Relapse? No!

Feat. J. Mikhael